Researchers from many international institutions have teamed up to design a more effective drug for liver cancer therapy. Their compound may help improve survival rates and reduce adverse effects. Hepatocellular carcinoma, or primary liver cancer, tends to grow and expand at a fast rate. If it is not caught early, this means that people who have been diagnosed with it may not survive longer than 11 months. In an effort to improve liver cancer treatment, researchers from the Cancer Institute of Singapore at the National University of Singapore in Queenstown have come together with colleagues from other global institutions to develop a new experimental drug, which they call "FFW."
To read the full story, visit: Medical News Today
New study evaluates efficacy of PET imaging to manage chronic liver diseases
EASL governing board announces new Vice-Secretary
A web-based program is as effective as group counseling for patients with non-alcoholic fatty liver disease